New 52-week results from the Phase 3 OptIMMize-1 clinical trial demonstrate that risankizumab provides sustained skin clearance, significant itch reduction, and improved quality of life in children and adolescents living with moderate-to-severe psoriasis. Dermatologists reviewing the data highlighted the therapy’s durable safety profile over a full year of treatment. Because chronic inflammatory skin conditions heavily impact pediatric mental health and sleep, the findings offer promising long-term management options for young patients.
About the Author
